What is the upside for Galectin Therapeutics'stock?
Their forecasts range from $14.00 to $14.00. On average, they anticipate Galectin Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 536.4% from the stock's current price. View analysts' price targets for Galectin Therapeutics or view top-rated stocks among Wall Street analysts.
What is the ticker symbol for Galectin Therapeutics?
Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT." Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' stock is owned by a number of institutional and retail investors.
What are analysts'price targets for Galectin Therapeutics'stock?
1 equities research analysts have issued 12-month price objectives for Galectin Therapeutics' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Galectin Therapeutics' share price to reach $14.00 in the next twelve months.
Where can I buy shares of Galt?
Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Should I buy or sell Galectin Therapeutics stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy...
What is Galectin Therapeutics' stock price forecast for 2022?
1 equities research analysts have issued 12 month price objectives for Galectin Therapeutics' stock. Their forecasts range from $11.00 to $11.00. O...
How has Galectin Therapeutics' stock performed in 2022?
Galectin Therapeutics' stock was trading at $2.07 at the beginning of 2022. Since then, GALT shares have decreased by 33.3% and is now trading at $...
When is Galectin Therapeutics' next earnings date?
Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for...
How were Galectin Therapeutics' earnings last quarter?
Galectin Therapeutics Inc. (NASDAQ:GALT) issued its earnings results on Monday, May, 16th. The company reported ($0.17) EPS for the quarter, missin...
Who are Galectin Therapeutics' key executives?
Galectin Therapeutics' management team includes the following people: Mr. Joel Lewis , Pres, CEO & Director (Age 52, Pay $838.44k) Mr. Jack W. C...
Who are some of Galectin Therapeutics' key competitors?
Some companies that are related to Galectin Therapeutics include Generation Bio (GBIO) , Affimed (AFMD) , Vaxxinity (VAXX) , Mersana Therapeuti...
What other stocks do shareholders of Galectin Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Thera...
What is Galectin Therapeutics' stock symbol?
Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."
What is Galectin Therapeutics's consensus rating and price target?
According to the issued ratings of 1 analysts in the last year, the consensus rating for Galectin Therapeutics stock is Buy based on the current 1...
Do Wall Street analysts like Galectin Therapeutics more than its competitors?
Analysts like Galectin Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Galectin Therapeutics is 3...
Do MarketBeat users like Galectin Therapeutics more than its competitors?
MarketBeat users like Galectin Therapeutics stock more than the stock of other Medical companies. 67.26% of MarketBeat users gave Galectin Therapeu...
Does Galectin Therapeutics's stock price have much upside?
According to analysts, Galectin Therapeutics's stock has a predicted upside of 773.02% based on their 12-month price targets.
What analysts cover Galectin Therapeutics?
Galectin Therapeutics has been rated by HC Wainwright in the past 90 days.
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr.
Signals & Forecast
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 6.59%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Galectin Therapeutics Inc. stock A Buy?
Galectin Therapeutics Inc. finds support from accumulated volume at $1.93 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Galectin Therapeutics Inc
Galectin Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Galectin Therapeutics Inc
In the last 100 trades there were 7.52 million shares bought and 177.5 thousand shares sold. The last trade was done 9 days ago by Lewis Joel who bough 8.45 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Galectin Therapeutics (NASDAQ:GALT) Price Target and Consensus Rating
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Galectin Therapeutics (NASDAQ:GALT) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Ideas
According to the issued ratings of 1 analysts in the last year, the consensus rating for Galectin Therapeutics stock is Buy based on the current 1 buy rating for GALT. The average twelve-month price target for Galectin Therapeutics is $14.00 with a high price target of $14.00 and a low price target of $14.00.
Profile
Several insider buys from board of directors members in recent days. CEO takes 80% pay in shares. The multi-billionaire chairman added $40 million stake in past couple years. Also, there is strong support at this price level.
Who is the chairman of Galectin Therapeutics?
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C.
Is galectin 3 a PD-1 inhibitor?
Richard E. Uihlein, Chairman of Galectin Therapeutics, commented on his $10 million investment, “This financing clearly illustrates that I remain deeply committed to the Company’s success and its goal of addressing large, unmet medical needs.
Is Galectin 3 good for cancer?
This clinical study constitutes proof-of-concept that the addition of our galectin-3 inhibitor, belapectin, to a PD-1 inhibitor can benefit cancer patients.
GALT earnings per share forecast
Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer.
GALT revenue forecast
What is GALT 's earnings per share in the next 3 years based on estimates from 1 analyst?
About Galectin Therapeutics Inc
What is GALT 's revenue in the next 3 years based on estimates from 1 analyst?
Golden Star Signal
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer.
Stock Podcast
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!